Camlin profit on Italian sale masks a still-lossmaking core
Consolidated profit of ₹2,762.72 lakh came from liquidating CPS Europe SpA and adding Vinpai. Standalone losses narrowed but the core business is still in the red.
— 3 earlier stories on Camlin Fine Sciences Ltd. →What's new
- Standalone net loss improved to ₹3,296.62 lakh from a prior-year loss of ₹7,631.05 lakh.
- Consolidated net profit was ₹2,762.72 lakh, boosted by liquidating CPS Europe SpA and including Vinpai.
- Board approved a new CFO and re-designated the current one.
Why this matters
The headline profit masks a still-lossmaking core. The gain came from selling an Italian subsidiary, not from the core business. The CFO change signals a reset in financial leadership.
What we're watching
- Whether the standalone loss can be turned into profit without one-off gains.
- The recurring contribution from Vinpai once the initial consolidation boost fades.
- Any further asset sales following the CPS Europe liquidation.
The full read
Camlin Fine Sciences' standalone net loss narrowed to ₹3,296.62 lakh from ₹7,631.05 lakh a year ago. That is a real improvement, but it is still a loss. The headline consolidated profit of ₹2,762.72 lakh tells a different story. It was powered by a gain from selling its Italian subsidiary, CPS Europe SpA, and adding Vinpai to the books for the first time. Those are one-off events, not a reflection of the core chemicals and preservatives business. The CFO shuffle adds another layer. Appointing a new finance chief while re-designating the old one signals a reset. The core question is whether management can turn a shrinking loss into real profit without relying on asset sales.
Questions answered
- Why was consolidated profit so much higher than the standalone loss?
- The consolidated figure included a one-off gain from liquidating CPS Europe SpA and the first-time inclusion of Vinpai. Neither represents recurring operational performance.
- How did the standalone results change versus last year?
- Standalone net loss narrowed to ₹3,296.62 lakh from ₹7,631.05 lakh. It is an improvement, but the core business remains loss-making.
- What are the management changes?
- The board approved the appointment of a new CFO and re-designated the incumbent CFO to a different role.
- Are these results a surprise?
- The filing notes the audited results were expected by the market, limiting their potential to move the stock significantly.
Camlin Fine Sciences Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on CAMLINFINE →- 26 May 2026 · 4:58 PM IST Camlin profit on Italian sale masks a still-lossmaking core
- 3d ago Camlin Fine's top R&D scientist resigns citing personal commitments
- 45d ago Camlin Fine Sciences cuts vanillin price guidance as costs surge
- 45d ago Camlin Fine Sciences cuts standalone losses, but revenue also shrank